Back

Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study

23 April 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Prevention of stroke in atrial fibrillation Oral Anticoagulation EHRA Premium Access EHRA 2021

About the speaker

Photo
Professor Joris R De Groot

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Contemporary data evaluating 1-year clinical outcomes in patients with atrial fibrillation and coexisting valvular heart disease: the ETNA-AF-Europe study
Professor F. Ricci (Chieti, IT)
Abstract Slides Video
Presentation thumbnail
Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe
Professor T. de Vries (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
Doctor S. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF
Doctor D. Morrone (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program
Doctor L. Dinshaw (Wismar, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention of stroke in atrial fibrillation

The Event

Event poster

EHRA 2021

23 April - 25 April 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources